|Novel interaction partners of the Cav2.2 channel
|Neurotransmission controlled by CaV2.2 or N-type calcium channels plays a major role in chronic and neuropathic pain which is a major clinical, social and economic problem. Ziconotide is the only one drug specifically targeting CaV2.2 channel. It is delivered intrathecally leaving demand for an oral drug open. Ion channels form macromolecular signaling complexes with a variety of interacting proteins and stabilization or disruption of such interactions may be a base for a novel therapeutic strategy. Modified yeast-two-hybrid assay identified proteins RTN1, SLC38A1, Ptgds, TMEM 223, and Grina as putative interaction partners of the CaV2.2 channels. These proteins are expressed predominantly or solely in neurons and several neuromodulatory functions of these proteins were described. We hypothesize that they may modulate CaV2.2 channels, as well.
|We will concentrate on following aspect of the CaV2.2 channel interactome:
|CaV2.2 channel, neuropathic pain, patch clamp, co-immunoprecipitation
|jún 2016 – január 2017